TY - THES A1 - Attia, Mohamad Ibrahim T1 - Design, synthesis and pharmacological evaluation of certain GABAB agonists T1 - Design, Synthese und pharmakologische Untersuchungen der GABAB-Agonisten N2 - Ziel dieser Arbeit war die Synthese von (RS)-5-Amino-3-aryl(methyl)-pentansäure Hydrochloride, 3-Aminomethyl-5-chlor-benzolsäure Hydrochlorid und(RS)-4-Amino-3-(4´-ethynyl(jod)-phenyl)-butansäure Hydrochloride und die Testung der pharmakologischen Aktivität dieser Verbindungen. Die synthetisierten Verbindungen wurden als GABAB-Rezeptor Agonisten, in einem auf Ca2+-Messungen basierenden Funktional-Assay (in vitro tsA Zellen mit GABAB1b/GABAB2/Gαq-z5 transfektiert), getestet und daraus ein Struktur-Aktivitäts Modell abgeleitet. Im allgemein Teil dieser Arbeit wird ein Überblick, über die Neurotransmitter- Rezeptoren (Liganden gesteuerte Ionen-Kanal-Rezeptoren und G Protein-gekoppelte Rezeptoren) des zentralen Nervensystems und deren Agonisten und Antagonisten, gegeben. Eine ausführliche Diskussion zur Synthesestrategie der Verbindungen der Zwischenstufen und der Ausgangsmaterialien wird in den Schemata 2-6 beschrieben. Die synthetisierten Verbindungen wurden als GABAB Agonisten geprüft. Zusätzlich wurden diese im 3D Homologie Modell mit FlexiDock Programm gedockt. Daraus wurde ein Modell zur Voraussage der Aktivität von Analogen und Homologen des Baclofens abgeleitet. Letztendlich wurde ein Pharmakophor-Modell für GABAB Agonisten mit DISCO (DIStance COmparisons) Programm erstellt. N2 - Synthesis of (RS)-5-amino-3-aryl (methyl)-pentanoic acid hydrochlorides, 3 aminomethyl-5-chloro-benzoic acid hydrochloride and (RS)-4-amino-3-(4`-ethynyl(iodo)-phenyl)-butanoic acid hydrochlorides have been accomplished. The aim of their synthesis was to evaluate their GABABR agonist activity and to derive a model which will correlate their structure with the observed pEC50. The GABABR agonist activity of the prepared compounds has been determined in functional assay based on calcium measurement in vitro using tsA cells transfected with GABAB1b/GABAB2/Gαq-z5. Reviews on the neurotransmitter receptors (ligand-gated ion channel receptors and G protein-coupled receptors), their agonists and antagonists have been given in the general part of this work. A detailed discussion on the strategy followed for the synthesis of the designed compounds as well as the starting materials and intermediates has been described and illustrated in Schemes 2-6. The synthesized compounds were evaluated for their GABABR agonist activity. Furthermore, these compounds were docked in the available 3D homology model of GABABR using the program FlexiDock implemented in SYBYL software. Subsequently, we derived a predictive model which correlates the experimentally determined pEC50 with the calculated binding energy of certain baclofen analogues and homologues. In addition, we used the program DISCO (DIStance COmparisons) implemented in SYBYL software to find the pharmacophore features of GABAB agonists. KW - Baclofen KW - Analoga KW - GABA-Rezeptor-Agonist KW - Pharmakologie KW - GABAB KW - Sythese KW - Baclofen KW - Pharmakologie KW - Molekular Modeling KW - GABAB KW - synthesis KW - baclofen KW - pharmacology KW - molecular modeling Y1 - 2003 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-7551 ER - TY - JOUR A1 - Peter, Stefanie A1 - Bultinck, Jennyfer A1 - Myant, Kevin A1 - Jaenicke, Laura A. A1 - Walz, Susanne A1 - Müller, Judith A1 - Gmachl, Michael A1 - Treu, Matthias A1 - Boehmelt, Guido A1 - Ade, Casten P. A1 - Schmitz, Werner A1 - Wiegering, Armin A1 - Otto, Christoph A1 - Popov, Nikita A1 - Sansom, Owen A1 - Kraut, Norbert A1 - Eilers, Martin T1 - H Tumor cell-specific inhibition of MYC function using small molecule inhibitors of the HUWE1 ubiquitin ligase JF - EMBO Molecular Medicine N2 - Deregulated expression of MYC is a driver of colorectal carcinogenesis, necessitating novel strategies to inhibit MYC function. The ubiquitin ligase HUWE1 (HECTH9, ARF-BP1, MULE) associates with both MYC and the MYC-associated protein MIZ1. We show here that HUWE1 is required for growth of colorectal cancer cells in culture and in orthotopic xenograft models. Using high-throughput screening, we identify small molecule inhibitors of HUWE1, which inhibit MYC-dependent transactivation in colorectal cancer cells, but not in stem and normal colon epithelial cells. Inhibition of HUWE1 stabilizes MIZ1. MIZ1 globally accumulates on MYC target genes and contributes to repression of MYC-activated target genes upon HUWE1 inhibition. Our data show that transcriptional activation by MYC in colon cancer cells requires the continuous degradation of MIZ1 and identify a novel principle that allows for inhibition of MYC function in tumor cells. KW - colorectal cancer KW - HUWE1 KW - MIZ1 KW - MYC KW - ubiquitination KW - cancer KW - digestive system KW - pharmacology KW - drug discovery Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-118132 SN - 1757-4684 VL - 6 IS - 12 ER - TY - JOUR A1 - Spinner, Christoph D A1 - Wille, Florian A1 - Schwerdtfeger, Christiane A1 - Thies, Philipp A1 - Tanase, Ursula A1 - Von Figura, Guido A1 - Schmid, Roland M A1 - Heinz, Werner J A1 - Klinker, Hartwig Hf T1 - Pharmacokinetics of chewed vs. swallowed raltegravir in a patient with AIDS and MAI infection: some new conflicting data JF - AIDS Research and Therapy N2 - Background: While HIV, AIDS and atypical Mycobacterium infections are closely linked, the use of Integrase-Inhibitor based cART, notably raltegravir-based regimens is more widespread. RAL should be double-dosed to 800 mg semi-daily in situation of rifampicin co-medication, because RAL is more rapidly metabolized due to rifampicin-induced Uridine-5'-diphosph-gluronosyl-transferase (UGT1A1). Recently, it was speculated that chewed RAL might lead to increased absorption, which might compensate the inductive effect of rifampicin-rapid metabolized RAL, as part of cost-saving effects in countries with high-tuberculosis prevalence and less economic power. Methods: We report measurement of raltegravir pharmacokinetics in a 34-year AIDS-patient suffering from disseminated Mycobacterium avium infection with necessity of parenteral rifampicin treatment. RAL levels were measured with HPLC (internal standard: carbamazepine, LLQ 11 ng/ml, validation with Valistat 2.0 program (Arvecon, Germany)). For statistical analysis, a two-sided Wilcoxon signed rank test for paired samples was used. Results: High intra-personal variability in raltegravir serum levels was seen. Comparable C\(_{max}\) concentrations were found for 800 mg chewed and swallowed RAL, as well as for 400 mg chewed and swallowed RAL. While C\(_{max}\) seems to be more dependent from overall RAL dosing than from swallowed or chewed tablets, increased AUC(12) is clearly linked to higher RAL dosages per administration. Anyway, chewed raltegravir showed a rapid decrease in serum levels. Conclusions: We found no evidence that chewed 400 mg semi-daily raltegravir in rifampicin co-medication leads to optimized pharmacokinetics. There is need for more data from randomized trials for further recommendations. KW - pharmacology KW - drug KW - HIV KW - chewed KW - Mycobacterium avium KW - raltegravir KW - pharmacokinetic Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-144058 VL - 12 IS - 1 ER - TY - JOUR A1 - Sarukhanyan, Edita A1 - Shityakov, Sergey A1 - Dandekar, Thomas T1 - In silico designed Axl receptor blocking drug candidates against Zika virus infection JF - ACS Omega N2 - After a large outbreak in Brazil, novel drugs against Zika virus became extremely necessary. Evaluation of virus-based pharmacological strategies concerning essential host factors brought us to the idea that targeting the Axl receptor by blocking its dimerization function could be critical for virus entry. Starting from experimentally validated compounds, such as RU-301, RU-302, warfarin, and R428, we identified a novel compound 2′ (R428 derivative) to be the most potent for this task amongst a number of alternative compounds and leads. The improved affinity of compound 2′ was confirmed by molecular docking as well as molecular dynamics simulation techniques using implicit solvation models. The current study summarizes a new possibility for inhibition of the Axl function as a potential target for future antiviral therapies. KW - free energy KW - molecular docking KW - molecular dynamics KW - simulation KW - pharmacology KW - proteins KW - structure-activity relationship KW - viruses KW - Zika virus Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-176739 VL - 3 IS - 5 ER - TY - THES A1 - Nemec, Katarina T1 - Modulation of parathyroid hormone 1 receptor (PTH1R) signaling by receptor activity-modifying proteins (RAMPs) T1 - Regulierung der Signalübertragung des Parathormon 1-Rezeptors (PTH1R) durch Rezeptoraktivitäts-modifizierende Proteine (RAMPs) N2 - The receptor activity-modifying proteins (RAMPs) are ubiquitously expressed membrane proteins that interact with several G protein-coupled receptors (GPCRs), the largest and pharmacologically most important family of cell surface receptors. RAMPs can regulate GPCR function in terms of ligand-binding, G-protein coupling, downstream signaling, trafficking, and recycling. The integrity of their interactions translates to many physiological functions or pathological conditions. Regardless of numerous reports on its essential importance for cell biology and pivotal role in (patho-)physiology, the molecular mechanism of how RAMPs modulate GPCR activation remained largely elusive. This work presents new insights that add to the common understanding of the allosteric regulation of receptor activation and will help interpret how accessory proteins - RAMPs - modulate activation dynamics and how this affects the fundamental aspects of cellular signaling. Using a prototypical class B GPCR, the parathyroid hormone 1 receptor (PTH1R) in the form of advanced genetically encoded optical biosensors, I examined RAMP's impact on the PTH1R activation and signaling in intact cells. A panel of single-cell FRET and confocal microscopy experiments as well canonical and non-canonical functional assays were performed to get a holistic picture of the signaling initiation and transduction of that clinically and therapeutically relevant GPCR. Finally, structural modeling was performed to add molecular mechanistic details to that novel art of modulation. I describe here that RAMP2 acts as a specific allosteric modulator of PTH1R, shifting PTH1R to a unique pre-activated state that permits faster activation in a ligand-specific manner. Moreover, RAMP2 modulates PTH1R downstream signaling in an agonist-dependent manner, most notably increasing the PTH-mediated Gi3 signaling sensitivity and kinetics of cAMP accumulation. Additionally, RAMP2 increases PTH- and PTHrP-triggered β-arrestin2 recruitment to PTH1R and modulates cytosolic ERK1/2 phosphorylation. Structural homology modeling shows that structural motifs governing GPCR-RAMP interaction originate in allosteric hotspots and rationalize functional modulation. Moreover, to interpret the broader role of RAMP's modulation in GPCRs pharmacology, different fluorescent tools to investigate RAMP's spatial organization were developed, and novel conformational biosensors for class B GPCRs were engineered. Lastly, a high throughput assay is proposed and prototyped to expand the repertoire of RAMPs or other membrane protein interactors. These data uncover the critical role of RAMPs in GPCR activation and signaling and set up a novel platform for studying GPCR modulation. Furthermore, these insights may provide a new venue for precise modulation of GPCR function and advanced drug design. N2 - G Protein-gekoppelte Rezeptoren (GPCRs) bilden die größte und pharmakologisch wichtigste Familie von Zelloberflächenrezeptoren, die zahlreiche (patho-)physiologische Prozesse im menschlichen Körper steuern. GPCRs übertragen während des Rezeptoraktivierungsprozesses extrazelluläre Signale in das Zellinnere, wo durch die extrazelluläre Stimulation Konformationsänderungen des Rezeptorkerns auslöst und die Bindung intrazellulärer Bindungspartner – G Proteine, G Protein-gekoppelte Rezeptorkinase und Arrestine - ermöglicht. Es handelt sich also um einen kritischen Prozess in der Signaltransduktion, der durch einige endogene Moleküle wie Ionen, Lipide oder andere Proteine moduliert werden kann und Auswirkungen auf nachgeschaltete Signalkaskaden hat. GPCRs bilden gewebeabhängige Oligomere mit ihren interagierenden Partnern, Rezeptor-Aktivitäts-modifizierende Proteinen (RAMPs), ubiquitär exprimierten Membranproteinen. Bekannt ist, dass sie die Ligandenbindung, die G- Protein-Kopplung, die nachgeschaltete Signalisierung, das Trafficking und das Recycling einiger GPCRs modulieren. Ihre Rolle im kritischsten Prozess der Signaltransduktion - der Rezeptoraktivierung - wurde jedoch nur begrenzt erforscht. Anhand des physiologisch und therapeutisch wichtigen Parathormon-Rezeptors (PTH1R), einem GPCR der Klasse B, wurden die Modulationseffekte von RAMPs auf den Prozess der Rezeptoraktivierung und ihre Folgen für die nachgeschaltete Signalübertragung analysiert. Hierzu wurden verschiedene optische Biosensoren zur Messung der Aktivierung des PTH1R und seiner Signalkaskade entwickelt und in verschiedenen Versuchsanordnungen eingesetzt, mit dem Ziel einen holistischen Blick auf die Interaktion zwischen PTH1R und RAMPs und ihre funktionellen Auswirkungen zu erhalten. Die Interaktion zwischen PTH1R und RAMPs erwies sich als besonders ausgeprägt für RAMP2, und RAMP2 zeigte eine spezifische allosterische Modulation der PTH1R-Konformation, sowohl im basalen als auch im Liganden- aktivierten Zustand. Ein einzigartiger voraktivierter oder (meta-stabiler) Zustand ermöglichte eine schnellere Rezeptoraktivierung auf Liganden-spezifische Weise. Außerdem beeinflusste RAMP2 die G Protein- und Nicht-G Protein-vermittelte Signalübertragung indem es die PTH-vermittelte Gi3-Signalempfindlichkeit und die Kinetik der cAMP-Akkumulation modulierte. Weiterhin erhöhte RAMP2 die Menge der β-Arrestin2-Rekrutierung an PTH1R auf Liganden-spezifische Weise. Dies könnte mit einer erhöhten zytosolischen ERK-Menge zusammenhängen, die hat sich von der nukleären ERK-Phosphorylierung unterscheidet. Um einen molekularen Mechanismus für die vorgestellten Ergebnisse vorzuschlagen, wurden mehrere strukturelle Modelle entwickelt und analysiert. Diese Arbeit liefert den Beweis, dass RAMP die GPCR-Aktivierung mit funktionellen Auswirkungen auf die zelluläre Signalübertragung reguliert. Die Ergebnisse sollten im Zusammenhang mit zellspezifischen Koexpressionsmustern interpretiert werden und können zur Entwicklung von fortschrittlichen Therapeutika positiv beitragen. Da GPCRs praktisch alle Zellfunktionen koordinieren und seit jeher wichtigen Angriffspunkten für Medikamente sind, tragen die vorgestellten Erkenntnisse zum universellen Verständnis der molekularen Mechanismen bei, die den menschlichen Körper orchestrieren. KW - G-Protein gekoppelter Rezeptor KW - GPCR KW - RAMP KW - PTH1R KW - FRET KW - BRET KW - pharmacology KW - Fluoreszenz-Resonanz-Energie-Transfer KW - Förster Resonanz Energie Transfer Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-288588 ER -